Apatinib 250mg

DRUG2 trials

Sponsors

West China Hospital, Ruijin Hospital

Conditions

ApatinibCombination ChemotherapyGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaLung CancerNon Small Cell Lung Cancer

Phase 1

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

West China HospitalApatinib, Combination Chemotherapy, Lung Cancer +1

Start: 2017-06-27End: 2020-08-01Target: 48Updated: 2017-11-17

Phase 2

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruitingNCT04208347

Ruijin HospitalGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Start: 2019-12-18End: 2027-12-01Target: 580Updated: 2026-01-23

Related Papers

PDPN+ cancer-associated fibroblasts correlate with the neoadjuvant immunotherapy response in gastric cancer

APL Bioengineering2025-08-281 citations

LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer.

2025-02-171 citations

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol

BMJ Open2024-02-016 citations

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.

2023-01-03163 citations

Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma

Annals of Translational Medicine2020-12-0117 citations

Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial

European Journal of Cancer2020-03-1159 citations